Şunu aradınız:: roflumilast (İngilizce - Maltaca)

treated with roflumilast.
b’roflumilast.

ratio roflumilast/placebo
proporzjon roflumilast/placebo

the active substance is roflumilast.
is-sustanza attiva hi roflumilast.

daliresp 500 micrograms tablets roflumilast
daliresp 500 mikrogramma pilloli roflumilast

each tablet contains 500 micrograms roflumilast.
kull pillola fiha 500 mikrogramma ta’ roflumilast.

each tablet contains 500 micrograms of roflumilast.
kull pillola fiha 500 mikrogramma ta’ roflumilast.

daliresp 500 micrograms film-coated tablets roflumilast
daliresp 500 mikrogramma pilloli miksija b’rita roflumilast

in patients with copd, roflumilast reduced sputum neutrophils.
f’pazjenti b’copd, roflumilast naqqas in-newtrofili fl-isputum.

roflumilast should not be used during breast-feeding.
roflumilast m’għandux jintuża waqt it-treddigћ.

daliresp is a medicine that contains the active substance roflumilast.
daliresp huwa prodott mediċinali li fih is-sustanza attiva roflumilast.

it is not known whether roflumilast is dialysable by peritoneal dialysis.
mhux magħruf jekk roflumilast jistax jitneħħa permezz ta’ dijalisi peritoneali.

roflumilast is not recommended in women of childbearing potential not using contraception.
roflumilast mhux rakkomandat lil nisa li jista’ jkollhom it-tfal li ma jużawx kontraċezzjoni

adverse reactions with roflumilast in clinical copd studies and post-marketing experience
reazzjonijiet avversi b’roflumilast fi studji kliniċi dwar copd

available pharmacokinetic data in animals have shown excretion of roflumilast or its metabolites in milk.
dejta farmakokinetika disponnibli fl-annimali uriet li kien hemm eliminazzjoni ta’ roflumilast jew tal-metaboliti tiegħu fil-ħalib tas-sider.

roflumilast improved lung function after 4 weeks (sustained over 52 weeks).
roflumilist tejjeb il-funzjoni tal-pulmun wara 4 ġimgħat (sostnut fuq 52 ġimgħa).

in this case, roflumilast treatment should be reassessed (see section 4.4).
f’dan il-każ, il-kura b’roflumilast għandha tiġi evalwata mill-ġdid (ara sezzjoni 4.4).

after discontinuation of roflumilast, the majority of patients had regained body weight after 3 months.
wara t-twaqqif ta’ roflumilast, il-maġġoranza tal-pazjenti kisbu lura l-piż tal-ġisem wara 3 xhur.

a combination of roflumilast with these active substances might lead to an increase of exposure and persistent intolerability.
kumbinazzjoni ta’ roflumilast ma’ dawn is-sustanzi attivi tista’ twassal għal żieda fl-espożizzjoni u intollerabilità persistenti.

roflumilast is associated with an increased risk of psychiatric disorders such as insomnia, anxiety, nervousness and depression.
roflumilast hu assoċjat ma’ żieda fir-riskju ta’ disturbi psikjatriċi bħal nuqqas ta’ rqad, ansjetà, nervożità u dipressjoni.

the plasma clearance after short-term intravenous infusion of roflumilast is about 9.6 l/h.
it-tneħħija mill-plażma wara infużjoni qasira ta’ roflumilast ġo vina hi madwar 9.6 l/siegħa.